Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: An analysis of a phase III randomized trial

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Yu Pei ^a   Chen, Yong ^a   Zhang, Wen Na ^a   Liang, Shao Bo ^b   Zong, Jing Feng ^c   Chen, Lei ^a   Mao, Yan Ping ^a   Tang, Ling Long ^a   Li, Wen Fei ^a   Liu, Xu ^a   Guo, Ying ^a   Lin, Ai Hua ^d   Liu, Meng Zhong ^a   Sun, Ying ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^c FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; CANCER STAGING; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADULT; AGED; BIOMARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84938117617     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12502     Document Type: Article

References (18)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90, doi: 10.3322/caac.20107 (2011).
2. Lai, S. Z. et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80, 661-668, doi: 10.1016/j.ijrobp.2010.03.024 (2011).
3. Chan, A. T. Current treatment of nasopharyngeal carcinoma. Eur J Cancer 47 Suppl 3, S302-303, doi:10.1016/S0959-8049(11)70179-4 (2011).
4. Chen, Y. et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71, 1356-1364, doi: 10.1016/j.ijrobp.2007.12.028 (2008).
5. Chen, Y. et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 119, 2230-2238, doi: 10.1002/cncr.28049 (2013).
6. Chen, Y. P. et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 26, 205-211, doi: 10.1093/annonc/mdu507 (2015).
7. Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8, 431-440 (1989).
8. Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53, 457-481 (1958).
9. Cox, D. R. Regression models and life-tables. J Royal Statist Soc Series B 34, 187-202 (1972).
10. Burzykowski, T., Molenberghs, G., Buyse, M., Geys, H. & Renard, D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C Appl Stat 50, 405-422 (2001).
11. Zeng, H. et al. Cancer survival in China, 2003-2005: A population-based study. Int J Cancer, doi: 10.1002/ijc.29227 (2014).
12. Lee, A. W. et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61, 1107-1116, doi: 10.1016/j.ijrobp.2004.07.702 (2005).
13. Baujat, B. et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64, 47-56, doi: 10.1016/j.ijrobp.2005.06.037 (2006).
14. Blanchard, P. et al. Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients. ASCO Meeting Abstracts 32, 6022 (2014).
15. Baker, S. G. Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst 98, 502-503, doi: 10.1093/jnci/djj153 (2006).
16. Ray, M. E. et al. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst 101, 228-236, doi: 10.1093/jnci/djn489 (2009).
17. Leung, S. F. et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 25, 1204-1208, doi: 10.1093/annonc/mdu117 (2014).
18. Liu, N. et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 13, 633-641, doi: 10.1016/S1470-2045(12)70102-X (2012).